PMID- 29464579
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20181202
IS  - 1867-0687 (Electronic)
VI  - 14
IP  - 3
DP  - 2018 Jun
TI  - Oxcarbazepine oral suspension in young pediatric patients with partial seizures 
      and/or generalized tonic-clonic seizures in routine clinical practice in China: a 
      prospective observational study.
PG  - 280-289
LID - 10.1007/s12519-017-0114-6 [doi]
AB  - BACKGROUND: This study aimed to assess efficacy and safety of oxcarbazepine (OXC) 
      oral suspension in pediatric patients aged 2-5 years with partial seizures (PS) 
      and/or generalized tonic-clonic seizures (GTCS) in real-world clinical practice 
      in China. METHODS: This 26-week, prospective, single-arm, multicenter, 
      observational study recruited pediatric patients aged 2-5 years with PS or GTCS 
      suitable for OXC oral suspension treatment based on physicians' judgments from 11 
      medical centers in China. Enrolled subjects started OXC oral suspension treatment 
      as monotherapy or in combination with other antiepileptic drugs. Primary efficacy 
      outcome was the percentage of pediatric subjects achieving >/= 50% seizure 
      frequency reduction at the end of the 26-week treatment. Secondary 
      efficacy-related parameters and safety parameters such as adverse events (AEs) 
      and serious AEs (SAEs) were also monitored during the 26-week treatment period. 
      RESULTS: Six hundred and six pediatric patients were enrolled and 531 (87.6%) 
      completed the study. After 26 weeks of treatment, 93.3% subjects achieved >/= 50% 
      seizure frequency reduction, and 81.8% achieved 100% seizure frequency reduction 
      compared to baseline. Among different seizure types, OXC was effective in all 
      subjects with simple PS and in > 90% of subject with other type of seizure 
      present in the study. AEs were observed in 49 (8.1%) subjects. Only three 
      subjects experienced SAE. Rash (n = 18, 2.97%) was the most common AE. Only 17 
      subjects discontinued due to AEs. CONCLUSION: This study, reporting the 
      real-world data, further confirms the efficacy and good safety profile of OXC 
      oral suspension in Chinese pediatric patients aged 2-5 years with PS and/or GTCS.
FAU - Qin, Jiong
AU  - Qin J
AD  - Department of Pediatrics, Peking University People's Hospital, No. 11 Xi Zhi Men 
      Nan Da Jie, Xicheng District, Beijing, 100044, China. jiongqinbeijing01@126.com.
AD  - Department of Pediatrics, Peking University First Hospital, Beijing, China. 
      jiongqinbeijing01@126.com.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Neurology, Children's Hospital, Fudan University, Shanghai, China.
FAU - Huang, Xin-Fang
AU  - Huang XF
AD  - Department of Pediatrics, Quanzhou Women's and Children's Hospital, Quanzhou, 
      China.
FAU - Zhang, Yu-Qin
AU  - Zhang YQ
AD  - Department of Neurology, Tianjin Children's Hospital, Tianjin, China.
FAU - Fang, Fang
AU  - Fang F
AD  - Department of Neurology, Beijing Children's Hospital, Beijing, China.
FAU - Chen, Yin-Bo
AU  - Chen YB
AD  - Department of Pediatric Neurology, The First Bethune Hospital, Jilin University, 
      Changchun, China.
FAU - Lin, Zhong-Dong
AU  - Lin ZD
AD  - Department of Pediatric Neurology, The 2nd Affiliated Hospital, Wenzhou Medical 
      University, Wenzhou, China.
FAU - Deng, Yan-Chun
AU  - Deng YC
AD  - Department of Neurology, Xijing Hospital, Xi'an, China.
FAU - Yin, Fei
AU  - Yin F
AD  - Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Jiang, Li
AU  - Jiang L
AD  - Department of Neurology, Children's Hospital, Chongqing Medical University, 
      Chongqing, China.
FAU - Wu, Ye
AU  - Wu Y
AD  - Department of Pediatrics, Peking University First Hospital, Beijing, China.
FAU - Hu, Xiang-Shu
AU  - Hu XS
AD  - The third Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou, 
      China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20180220
PL  - Switzerland
TA  - World J Pediatr
JT  - World journal of pediatrics : WJP
JID - 101278599
RN  - 0 (Anticonvulsants)
RN  - 33CM23913M (Carbamazepine)
RN  - VZI5B1W380 (Oxcarbazepine)
SB  - IM
MH  - Administration, Oral
MH  - Age Factors
MH  - Anticonvulsants/adverse effects/*therapeutic use
MH  - Carbamazepine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Child, Preschool
MH  - China
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Epilepsy, Tonic-Clonic/diagnosis/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Oxcarbazepine
MH  - Prospective Studies
MH  - Seizures/diagnosis/*drug therapy
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiepileptic drugs
OT  - Generalized tonic-clonic seizures
OT  - Oxcarbazepine oral suspension
OT  - Partial seizures
OT  - Pediatric patients
EDAT- 2018/02/22 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/02/22 06:00
PHST- 2016/11/09 00:00 [received]
PHST- 2017/04/17 00:00 [accepted]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2018/02/22 06:00 [entrez]
AID - 10.1007/s12519-017-0114-6 [pii]
AID - 10.1007/s12519-017-0114-6 [doi]
PST - ppublish
SO  - World J Pediatr. 2018 Jun;14(3):280-289. doi: 10.1007/s12519-017-0114-6. Epub 
      2018 Feb 20.